Today analysts at Mizuho Securities reiterated Laboratory Corp. Of America Holdings’s (NYSE:LH) shares as ‘Neutral’ in a report released to investors.
According to Mizuho Securitiess price target of 139 on the company’s stock this indicates the broker now believes there is an increase of 0.1% from Laboratory Corp. Of America Holdings’s current price of 138.86.
In the last year Laboratory Corp. Of America Holdings’s stock price has increased by 31.25% from 105.8 to 138.86.
The number of Laboratory Corp. Of America Holdings shares in issue is 103,000,000 which have a current share price of 138.86 bringing Laboratory Corp. Of America Holdings’s market capitalisation to 14.30B USD.
The 52 week high of shares in Laboratory Corp. Of America Holdings is 141.32 while the 52 week low for the company’s shares is 106.01. The businesses 50 day moving average is 133.14 and its 200 day moving average is 132.91.
Laboratory Corporation of America Holdings is a healthcare diagnostics company. The Company, together with its subsidiaries, is engaged in providing clinical laboratory services and drug development support. The Company operates through two segments: LabCorp Diagnostics (LCD) and Covance Drug Development (CDD). The Company’s LCD segment is an independent clinical laboratory business that consists of a network of approximately 40 primary laboratories and approximately 1,700 patient service centers (PSCs) along with a network of branches and STAT laboratories, which offer a menu of routine and frequently ordered tests. LCD offers a menu of over 4,700 tests, such as blood chemistry analyses, urinalyses, blood cell counts and thyroid tests. Its CDD segment offers drug development services, and provides a range of drug development solutions across the world, primarily to companies in the pharmaceutical and biotechnology industries.